Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multi-Center, Randomized, Double-Masked, Saline-Controlled Trial to Evaluate the Effect of NOV03 (Perfluorohexyloctane) on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)

Next Previous
Trial Profile

A Phase 3, Multi-Center, Randomized, Double-Masked, Saline-Controlled Trial to Evaluate the Effect of NOV03 (Perfluorohexyloctane) on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 25 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Perfluorohexyloctane (Primary)
  • Indications Dry eyes
  • Focus Registrational; Therapeutic Use
  • Acronyms Gobi Study
  • Sponsors Bausch Health Companies; Novaliq

Most Recent Events

  • 28 May 2024 According to a Bausch & Lomb media release, data from this study will be presented during the American Optometric Association (AOA) Optometry's Meeting ePoster Session, taking place virtually May 29-30, 2024.
  • 08 Jun 2023 According to a Bausch & Lomb media release, data from this study will be presented during the American Optometric Association (AOA) Optometrys Meeting e-posters Virtual Event,
  • 18 May 2023 According to a Bausch & Lomb media release, based on results from GOBI and MOJAVE, the U.S. Food and Drug Administration (FDA) has approved MIEBO (perfluorohexyloctane ophthalmic solution; formerly known as NOV03), for the treatment of the signs and symptoms of dry eye disease (DED).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top